HPGC Renmintongtai Pharmaceutical Corporation (SHA:600829)

SHA:600829 Revenue

HPGC Renmintongtai Pharmaceutical had revenue of 2.70B CNY in the quarter ending September 30, 2026, with 0.06% growth. This brings the company's total for the last twelve months to 10.64B, up 4.14% year-over-year. In the year 2025, HPGC Renmintongtai Pharmaceutical had annual revenue of 10.38B with 3.29% growth. That makes HPGC Renmintongtai Pharmaceutical the 5,756th largest company in the world by revenue and 759th in China.

• Revenue (ttm): 10.64B
• Revenue Growth: +4.14%
• P/S Ratio: 0.47
• Revenue / Employee: 3.89M
• Employees: 2,735
• Market Cap: 5.05B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Pharmaceutical Commercial 10.27B 99.3%
• Others 71.98M 0.7%

Fiscal year ended Dec 31, 2025 See the full SHA:600829 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	10.38B	330.43M	3.29%
Dec 31, 2024	10.05B	-341.70M	-3.29%
Dec 31, 2023	10.39B	748.89M	7.77%
Dec 31, 2022	9.64B	325.86M	3.50%
Dec 31, 2021	9.32B	1.31B	16.36%

Data Source: S&P Global Market Intelligence Last updated: Oct 19, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 23, 2026

Data Sources Report a data error